期刊
CLINICAL CHEMISTRY
卷 59, 期 1, 页码 75-84出版社
AMER ASSOC CLINICAL CHEMISTRY
DOI: 10.1373/clinchem.2012.185157
关键词
-
资金
- AstraZeneca
- Cancer Research UK [13239] Funding Source: researchfish
- National Institute for Health Research [CL-2008-22-001] Funding Source: researchfish
BACKGROUND: Major advances in our understanding of the underlying biology of prostate cancer have helped to herald a new era in the treatment of castration-resistant prostate cancer (CRPC), with 5 new agents having shown a survival advantage in the last 3 years and an impressive number of promising novel agents now entering the clinic. CONTENT: We discuss the challenges facing drug development for CRPC and strategies to meet these challenges, with a focus not only on the development of predictive and intermediate endpoint biomarkers, but also on novel hypothesis-testing, biomarker-driven clinical trial designs. SUMMARY: With several promising agents now entering the clinic, there is increasing pressure to rethink drug development for CRPC to ensure that novel agents are appropriately evaluated and that patients and resources are appropriately allocated. We envision that biomarker-driven, reiterative clinical trials will have a major impact on CRPC treatment through the testing of robust scientific hypotheses with rationally designed drugs and drug combinations administered to selected patients. (C) 2012 American Association for Clinical Chemistry
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据